New Biosensor, MetaRing, Offers Rapid Breast Cancer Drug Sensitivity Analysis
Rapid and precise assessment of drug sensitivity is crucial for optimizing chemotherapy and improving patient outcomes in breast cancer treatment. Traditional chemosensitivity tests can be leisurely, require substantial sample volumes, and struggle with the complexities of biological samples. However, a newly developed programmable plasmonic ring biosensor, called MetaRing, promises to overcome these limitations, offering a faster and more accurate method for identifying paclitaxel sensitivity in breast cancer patients.
How MetaRing Works
Developed by a research team led by Prof. WANG Hongzhi from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, MetaRing is based on the “coffee-ring effect.” This phenomenon allows for deterministic nanoparticle assembly, forming hierarchical structures with dense and stable nanogaps. By carefully controlling nanoparticle concentration and evaporation temperature, the platform enhances detection stability and robustness across various biological environments, including water, buffer solutions, protein-rich media, and complex cell lysates. Source
Surface-Enhanced Raman Spectroscopy for Molecular Fingerprinting
MetaRing integrates surface-enhanced Raman spectroscopy (SERS) to capture molecular “fingerprints” with high sensitivity. This enables the rapid acquisition of metabolic spectra that reflect tumor cell responses to paclitaxel. The platform requires only trace amounts of biological samples and eliminates the necessitate for labeling or cell culture expansion. Source
Proven Accuracy in Multiple Samples
Experimental results demonstrate MetaRing’s ability to reliably identify paclitaxel sensitivity signatures in drug-resistant breast cancer cell lines, xenograft models, and patient-derived biopsy tissues. When combined with a lightweight one-dimensional convolutional neural network, the integrated MetaRing-AI system can complete drug sensitivity assessments within 10 minutes, achieving over 92% classification accuracy in clinical cohorts. Source
Potential for Personalized Chemotherapy
This research provides a practical strategy for rapidly evaluating paclitaxel sensitivity, supporting personalized chemotherapy approaches and addressing the challenges posed by inter-patient variability and tumor heterogeneity. The development of MetaRing holds strong potential for clinical translation, offering a more efficient and effective way to guide treatment decisions in breast cancer. Source
About Prof. Wang Hongzhi
Prof. WANG Hongzhi of the Chinese Academy of Sciences has a strong research background, with over 2,446 citations from 2,268 documents. Source He also led the development of another sensor chip, PlasmoBridge, which enables ultrasensitive and rapid monitoring of biomolecular interactions. Source